id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-N-3466-0001,FDA,FDA-2026-N-3466,Notice of Approval of Product Under Voucher: Rare Pediatric Disease Priority Review Voucher; MRESVIA (Respiratory Syncytial Virus Vaccine),Notice,Notice of Approval,2026-04-16T04:00:00Z,2026,4,,,2026-04-16T18:40:24Z,2026-07370,0,0,09000064b9286529